Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY is a prestigious academic journal dedicated to advancing the field of pharmaceutical biotechnology by publishing high-quality research articles, reviews, and innovatory methodologies. Published by Bentham Science Publishers Ltd, this journal has established a strong reputation in its field, reflected in its 2023 Scopus rankings: it holds an impressive Q2 classification in Pharmaceutical Science and Q3 in Biotechnology, indicating its significant impact within these disciplines. With an ISSN of 1389-2010 and an E-ISSN of 1873-4316, CURRENT PHARMACEUTICAL BIOTECHNOLOGY provides a reliable platform for disseminating valuable research findings and fostering collaboration among researchers, professionals, and students alike. The journal covers a wide array of topics, from drug development and delivery systems to innovative biotechnological techniques, thus serving as an essential resource for anyone interested in the cross-section of pharmaceutical science and biotechnology. Researchers can access a diverse range of articles that explore both theoretical frameworks and practical applications, reflecting the ongoing evolution and challenges in this dynamic field.

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

Medicinal Chemistry is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of drug discovery and development. Established in 2005 with a converged publication timeframe extending to 2024, this journal serves as a vital resource for researchers and professionals interested in the intricate processes of medicinal chemistry, pharmacology, and toxicology. With an ISSN of 1573-4064 and an E-ISSN of 1875-6638, it has established a notable presence in the academic community, currently positioned in Q3 of Drug Discovery category according to the 2023 quartiles. The journal's ranking in Scopus places it at 90 out of 157 in its field, showcasing its impact and relevance, with a percentile standing of 42. Although the journal is not open access, it continues to provide insightful articles and research findings that contribute significantly to the understanding and innovation in medicinal chemistry. Based in the United Arab Emirates, Medicinal Chemistry is committed to disseminating high-quality research that shapes the future of drug formulation and therapeutic advancement.

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

Journal of Natural Medicines, published by SPRINGER JAPAN KK, is a leading academic journal that plays a pivotal role in the advancement of research in the fields of Complementary and Alternative Medicine, Drug Discovery, Molecular Medicine, Organic Chemistry, and Pharmaceutical Science. Established in 1994 and set to continue until 2024, this journal serves as a vital conduit for the dissemination of groundbreaking research and innovative ideas that bridge traditional medicinal knowledge and modern scientific inquiry. With its impressive ranking in Scopus—ranking #12 out of 105 in Complementary and Alternative Medicine and holding a Q1 category quartile for 2023—it stands as a reputable source for high-quality, peer-reviewed articles. The journal's commitment to excellence is further underscored by its inclusion in the Springer network, providing researchers, professionals, and students with valuable insights and the latest developments in natural medicines. Although this journal operates under a subscription model, its profound impact on these interdisciplinary fields makes it an essential resource for anyone engaged in the study or practice of natural medicinal therapies.